ArriVent BioPharma, Inc. (AVBP) announced its plan to offer and sell $75 million of common stock.
The company intends to use the net proceeds along with existing cash to advance firmonertinib and other pipeline programs. It will also allocate funds for working capital and general corporate purposes.
Goldman Sachs & Co. LLC, Citigroup, and Guggenheim Securities are serving as joint book-running managers for the offering.
